Related Experiment Video
Updated: Jul 13, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent
1University of Lund, Lund, Sweden. uhe@novonordisk.com
Neuroradiology
|July 27, 2007
Summary
Recombinant activated coagulation factor VII (rFVIIa) offers a treatment for hemophilia patients with inhibitors. This breakthrough in hemostasis research highlights the crucial role of cell surfaces in blood clotting.
Area of Science:
- Hematology
- Biochemistry
- Molecular Biology
Background:
- Hemophilia is a severe bleeding disorder with a significantly reduced life expectancy.
- Patients with hemophilia often develop inhibitors to standard replacement therapies.
- Recombinant activated coagulation factor VII (rFVIIa) was developed as an alternative treatment for hemophilia.
Purpose of the Study:
- To investigate the efficacy of rFVIIa in treating hemophilia patients with inhibitors.
- To explore the role of FVII and tissue factor (TF) in hemostasis.
- To re-evaluate existing hemostatic models by incorporating cellular components.
Main Methods:
- Utilized rFVIIa for treatment of hemophilia patients with inhibitors.
- Stimulated research into the mechanisms of FVII and TF in coagulation.
- Examined the role of cell membranes and phospholipids in hemostasis.
Main Results:
- rFVIIa demonstrated effectiveness in inducing hemostasis, independent of FVIII or FIX.
- Research revealed a revised understanding of the hemostatic process.
- The importance of platelets and cell membrane phospholipids in hemostasis was highlighted.
Conclusions:
- rFVIIa is a viable therapeutic option for hemophilia patients with inhibitors.
- Hemostasis models need to incorporate cellular interactions for a comprehensive understanding.
- Cell surfaces play a critical role in the coagulation cascade.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.